ArticlePDF Available

Verrucous carcinoma of the vulva: About a case report

Authors:

Abstract and Figures

Introduction: Verrucous carcinoma of the vulva is a rare lesion, mainly affecting postmenopausal women, this lesion is a distinct and particular entity in the classification of vulvar carcinomas and its progression is uncertain and unpredictable. It is characterized by its extensive exophytic growth without infiltration of the basement membrane. Case Report: We report a case of verrucous carcinoma of the vulva collected at the Mohamed VI cancer treatment center in Casablanca, we will discuss through a literature review, its therapeutic and evolutionary diagnostic modalities. Conclusion: Therefore, verrucous carcinoma is a rare entity and its evolution is mainly local, rarely metastatic. It is the indication for exclusive surgical treatment with wide excision without lymphadenectomy in principle. Radiation therapy provides no survival benefit. The prognosis is relatively good but burdened by local recurrences.
Content may be subject to copyright.
Journal of Case Reports and Images in Obstetrics and Gynecology, Volume 9, Issue 1, 2023; Pages 49–52. ISSN: 2582-0249
J Case Rep Images Obstet Gynecol 2023;9(1):49–52.
www.ijcriog.com
El Abbassi et al. 49
CASE REPORT OPEN ACCESS
Verrucous carcinoma of the vulva: About a case report
Imane El Abbassi, S Tangara, D El Karoini, M Sakim, M Ennachit,
M Benhessou, M El Kerroumi
ABSTRACT
Introduction: Verrucous carcinoma of the vulva is a
rare lesion, mainly affecting postmenopausal women,
this lesion is a distinct and particular entity in the
classification of vulvar carcinomas and its progression
is uncertain and unpredictable. It is characterized by its
extensive exophytic growth without infiltration of the
basement membrane.
Case Report: We report a case of verrucous carcinoma
of the vulva collected at the Mohamed VI cancer treatment
center in Casablanca, we will discuss through a literature
review, its therapeutic and evolutionary diagnostic
modalities.
Conclusion: Therefore, verrucous carcinoma is a rare
entity and its evolution is mainly local, rarely metastatic.
It is the indication for exclusive surgical treatment with
wide excision without lymphadenectomy in principle.
Radiation therapy provides no survival benefit. The
prognosis is relatively good but burdened by local
recurrences.
Keywords: Verrucous carcinoma, Vulva, Vulvectomy
How to cite this article
El Abbassi I, Tangara S, El Karoini D, Sakim M,
Ennachit M, Benhessou M, El Kerroumi M. Verrucous
carcinoma of the vulva: About a case report. J Case
Rep Images Obstet Gynecol 2023;9(1):49–52.
Imane El Abbassi1, S Tangara1, D El Karoini1, M Sakim1, M
Ennachit1, M Benhessou1, M El Kerroumi1
Affiliation: 1Mohamed VI Center for the Treatment of Gyneco-
Mammary Cancers, CHU IBN Rochd, Casablanca, Morocco.
Corresponding Author: Imane El Abbassi, Mohamed VI Cent-
er for the Treatment of Gyneco-Mammary Cancers, CHU IBN
Rochd, Casablanca, Morocco; Email: imane.mammeri.im@
gmail.com
Received: 05 February 2023
Accepted: 21 March 2023
Published: 26 April 2023
Article ID: 100145Z08IA2023
*********
doi: 10.5348/100145Z08IA2023CR
INTRODUCTION
Vulvar cancers represent less than 5% of all female
genital cancers, and most often affect postmenopausal
women over the age of 60 [1]. Verrucous cancer is a
rare entity constituting less than 1% of vulvar cancers,
and is characterized by an exophytic appearance and
slow growth, rarely metastatic to the lymph nodes [2].
Indeed, it is a well-differentiated form of squamous cell
carcinoma linked to viral infection by HPV 6, having the
appearance of giant condyloma without invasion of the
basement membrane [3]. It has a mainly local evolution,
therefore represents the indication for exclusive surgical
treatment with local resection in a healthy zone without
systematic inguinal lymph node control [4, 5]. We report
a case of verrucous carcinoma of the vulva, treated at
the Mohamed VI cancer treatment center in Casablanca,
reflecting the diagnostic and therapeutic particularities of
this pathology.
CASE REPORT
We report the case of a 64-year-old patient, nulligest,
menopausal for 10 years, having a history as her sister
followed for breast cancer. She consulted for a whitish
vulvar lesion associated with vulvar itching evolving for
10 months before her admission, without associated
digestive or urinary signs. All evolving in a context of
conservation of the general state.
The clinical examination revealed a whitish exophytic
lesion of the vulva involving both the right labia minora
and the clitoris measuring 3×2.5 cm, the lymph node
areas were unharmed (Figure 1).
A vulvar biopsy was performed at this level, showing
a well-differentiated verrucous carcinoma. The pelvic
CASE REPORT PEER REVIEWED | OPEN ACCESS
Journal of Case Reports and Images in Obstetrics and Gynecology, Volume 9, Issue 1, 2023; Pages 49–52. ISSN: 2582-0249
J Case Rep Images Obstet Gynecol 2023;9(1):49–52.
www.ijcriog.com
El Abbassi et al. 50
A total vulvectomy alone without lymph node dissection
was performed. The anatomopathological result confirmed
the diagnosis of a verrucous squamous cell carcinoma with
healthy resection limits.
DISCUSSION
Verrucous carcinoma is a rare histological variety,
only 68 cases have been reported in the literature [6], is
characterized by diagnostic and prognostic particularities
that should be known to adapt the therapeutic attitude.
Indeed, it can occur in the vulva, the ear, nose, throat
(ENT) sphere, the penis, the scrotum, or the rectum [7].
Diagnosis, too, can be difficult to make. For this reason,
large biopsies should be performed to avoid misdiagnosis
and inadequate treatment [8].
Verrucous carcinomas exhibit several histological
diagnostic criteria such as a “pushed” tumor-dermis
interface with minimal stroma between the acanthotic
epithelium, minimal nuclear atypia, hyperkeratotic areas
on the surface of the tumor with little keratin formation at
inside the tumor and diffuse chronic inflammation of the
stroma [9]. It is locally invasive but rarely metastasizing,
usually affecting older postmenopausal women, which
is consistent with our study. However, its incidence is
currently increasing in young women [2, 10]. Indeed, it
is a well-differentiated form of squamous cell carcinoma
linked to viral infection by HPV 6, found in more than
50% of cases [3, 5], sometimes associated with polyviral
involvement, which explains the frequent association
of verrucous carcinoma of the vulva with intraepithelial
neoplasia and invasive carcinoma of the vulva [5, 11].
Its appearance is characterized by its significant
exophytic growth [12]: it is a budding lesion, cauliflower,
sometimes associated with a superficial ulceration. This
aspect can lead to the incorrect diagnosis of condyloma
acuminata or well-differentiated squamous cell carcinoma
[7, 13]. Thus, a biopsy that is too superficial and does not
include the underlying stroma may underestimate the lesion
giving an erroneous diagnosis of condyloma acuminata or
overestimate it giving a wrong diagnosis of squamous cell
carcinoma of another degree of differentiation [14].
It is therefore essential that the biopsy includes the
entire thickness of the lesion: the epithelium and a sufficient
quantity of chorion in order to avoid an inadequate
diagnosis and treatment [2, 5]. Microscopic examination
shows hyperplasia with hyperacanthosis, papillomatosis,
and sometimes surface hyperkeratosis. Cellular atypia and
mitosis are rare. Epithelial buds are branched but rounded
pushing back the underlying chorion. As for the basal
membrane, it is always respected [7, 15].
The treatment of verrucous carcinomas of the vulva
differs from that proposed for squamous cell carcinomas
[16]. However, although it is still a subject of discussion,
verrucous carcinoma of the vulva is the indication
for exclusive surgical treatment even in the event of
recurrence. Indeed, wide resection with a centimetric
Figure 1: Whitish exophytic lesion of the vulva involving both the
right labia minora and the clitoris measuring 3×2.5 cm.
ultrasound was without abnormality, a pelvic and inguinal
magnetic resonance image (MRI) was done highlighting
a tissue thickening of the right labia minora with an
intermediate signal on T2, in hypersignal intermediate
apparent diffusion coefficient (ADC) diffusion, enhanced
after injection of the phosphatidyl choline (PDC),
measuring 20×17×6 mm. Laterally this process comes
into contact with the large homolateral lip with loss of
the fibrous border of separation. It respects the ureteral
meatus (Figure 2).
Figure 2: Radiological appearance of the vulvar lesion.
Journal of Case Reports and Images in Obstetrics and Gynecology, Volume 9, Issue 1, 2023; Pages 49–52. ISSN: 2582-0249
J Case Rep Images Obstet Gynecol 2023;9(1):49–52.
www.ijcriog.com
El Abbassi et al. 51
margin without dissection in principle is the reference
treatment because of its attenuated local malignancy [17].
However, the extension of the lesions can nevertheless
make the gesture dilapidating. Thus, dissection can only
be justified if the definitive examination revealed the
presence of a true invasive zone [3, 5], since it exposes to
the risk of complications such as lymphocele (40%), scar
infection (39%), lymphedema (28%), and suture disunity
(17%) [8]. Moreover, radiotherapy does not provide
any survival benefit. It can even induce post-radiation
anaplastic transformation with the appearance of lesions
with high metastatic potential [18].
The prognosis is relatively good in the event of wide
excision but is burdened by local recurrences and the
risk of appearance of secondary localizations in the event
of persistence of the etiological factors (atrophic lichen
sclerosis or HPV) [2, 4, 5]. This justifies clinical monitoring
every four months during the first year, every six months
for two years then every year with a clinical examination
of the vulva, perineum, and lymph node areas, possibly
supplemented by ultrasound, cytopuncture, and smear
screening [4].
CONCLUSION
Therefore, verrucous carcinoma is a rare entity, well-
differentiated histological form of squamous cell carcinoma
which is distinguished by its particular diagnostic,
therapeutic, and evolutionary modalities. Its treatment is
exclusively surgical based on wide excision without lymph
node dissection. The prognosis of these lesions is good but
burdened by local recurrences.
REFERENCES
1. Dahbi Z, Elmejjatti F, Naciri F, et al. Vulvar cancer
treatment options: Experience in the Oncology
Center in Oujda. [Article in French]. Pan Afr Med J
2018;31:182.
2. Greer BE, Koh WJ. New NCCN guidelines for
vulvar cancer. J Natl Compr Canc Netw 2016;14(5
Suppl):656–8.
3. Khouchani M, Benchakroun N, Tahri A, et al. Breast
metastasis from vulvar carcinoma: Case report and
review of literature. [Article in French]. Cancer
Radiother 2008;12(2):120–5.
4. Leblanc E, Narducci F, Boukerrou M, Querleu D.
Chirurgie du cancer de la vulve. EMC - Techniques
Chirurgicales - Gynécologie 2007;23(1):1–16.
5. Allouache N, Blanc-Fournier C, Crouet H, et al. Vulvar
cancers: Diagnostic and therapeutic management.
RRC_GYN_Vulva Update February 2011.
6. Louis-Sylvestre C, Chopin N, Constancis E, Plantier F,
Paniel BJ. Verrucous carcinoma of the vulva: A tailored
treatment. [Article in French]. J Gynecol Obstet Biol
Reprod (Paris) 2003;32(7):634–7.
7. de Koning MNC, Quint WGV, Pirog EC. Prevalence of
mucosal and cutaneous human papillomaviruses in
different histologic subtypes of vulvar carcinoma. Mod
Pathol 2008;21(3):334–44.
8. Aynaud O, Asselain B, Bergeron C, et al. Intraepithelial
carcinoma and invasive carcinoma of the vulva, vagina
and penis in Ile-de-france. Enquete PETRI on 423
cases. [Article in French]. Ann Dermatol Venereol
2000;127(5):479–83.
9. Pape O, Lopès P, Bouquin R, et al. Interest of
selective lymphadenectomy in patients with vulvar
cancer. [Article in French]. Gynecol Obstet Fertil
2006;34(12):1105–10.
10. Baldwin P, Latimer J. Vulvar cancer. Current Obstetrics
& Gynecology 2005;15(2):113–22.
11. Zaidi H, Mouhajir N, El Mejjaou S, et al. Cancers
primitifs invasifs de la vulve: Expérience de l’Institut
National d’Oncologie de Rabat. Pan African Medical
Journal 2013;15:146.
12. Raspagliesi F, Hanozet F, Ditto A, et al. Clinical
and pathological prognostic factors in squamous
cell carcinoma of the vulva. Gynecol Oncol
2006;102(2):333–7.
13. Ghurani GB, Penalver MA. An update on vulvar cancer.
Am J Obstet Gynecol 2001;185(2):294–9.
14. van der Steen S, van de Nieuwenhof HP, Massuger L,
Bulten J, de Hullu JA. New FIGO staging system of
vulvar cancer indeed provides a better reflection of
prognosis. Gynecol Oncol 2010;119(3):520–5.
15. Boutas I, Sofoudis C, Kalampokas E, Anastasopoulos
C, Kalampokas T, Salakos N. Verrucous carcinoma
of the vulva: A case report. Case Rep Obstet Gynecol
2013;2013:932712.
16. Lanneau GS, Argenta PA, Lanneau MS, et al. Vulvar
cancer in young women: Demographic features
and outcome evaluation. Am J Obstet Gynecol
2009;200(6):645.e1–5.
17. Johann S, Klaeser B, Krause T, Mueller MD. Comparison
of outcome and recurrence-free survival after sentinel
lymph node biopsy and lymphadenectomy in vulvar
cancer. Gynecol Oncol 2008;110(3):324–8.
18. Moore DH. Chemotherapy and radiation therapy in
the treatment of squamous cell carcinoma of the vulva:
Are two therapies better than one? Gynecol Oncol
2009;113(3):379–83.
*********
Author Contributions
Imane El Abbassi – Conception of the work, Design of the
work, Acquisition of data, Analysis of data, Interpretation
of data, Drafting the work, Revising the work critically
for important intellectual content, Final approval of the
version to be published, Agree to be accountable for all
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved
S Tangara – Conception of the work, Design of the work,
Acquisition of data, Analysis of data, Interpretation of
data, Drafting the work, Revising the work critically for
important intellectual content, Final approval of the
version to be published, Agree to be accountable for all
aspects of the work in ensuring that questions related
Journal of Case Reports and Images in Obstetrics and Gynecology, Volume 9, Issue 1, 2023; Pages 49–52. ISSN: 2582-0249
J Case Rep Images Obstet Gynecol 2023;9(1):49–52.
www.ijcriog.com
El Abbassi et al. 52
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved
D El Karoini – Conception of the work, Design of the
work, Acquisition of data, Analysis of data, Interpretation
of data, Drafting the work, Revising the work critically
for important intellectual content, Final approval of the
version to be published, Agree to be accountable for all
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved
M Sakim – Conception of the work, Design of the work,
Acquisition of data, Analysis of data, Interpretation of
data, Drafting the work, Revising the work critically for
important intellectual content, Final approval of the
version to be published, Agree to be accountable for all
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved
M Ennachit – Conception of the work, Design of the
work, Acquisition of data, Analysis of data, Interpretation
of data, Drafting the work, Revising the work critically
for important intellectual content, Final approval of the
version to be published, Agree to be accountable for all
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved
M Benhessou – Conception of the work, Design of the
work, Acquisition of data, Analysis of data, Interpretation
of data, Drafting the work, Revising the work critically
for important intellectual content, Final approval of the
version to be published, Agree to be accountable for all
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved
M El Kerroumi – Conception of the work, Design of the
work, Acquisition of data, Analysis of data, Interpretation
of data, Drafting the work, Revising the work critically
for important intellectual content, Final approval of the
version to be published, Agree to be accountable for all
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved
Guarantor of Submission
The corresponding author is the guarantor of submission.
Source of Support
None.
Consent Statement
Written informed consent was obtained from the patient
for publication of this article.
Conflict of Interest
Authors declare no conflict of interest.
Data Availability
All relevant data are within the paper and its Supporting
Information files.
Copyright
© 2023 Imane El Abbassi et al. This article is distributed
under the terms of Creative Commons Attribution
License which permits unrestricted use, distribution
and reproduction in any medium provided the original
author(s) and original publisher are properly credited.
Please see the copyright policy on the journal website for
more information.
Access full text article on
other devices
Access PDF of article on
other devices
Submit your manuscripts at
www.edoriumjournals.com
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Vulvar cancer is a rare neoplastic disorder accounting for less than 5% of female genital cancers. This study aims to describe the epidemiological, clinical, paraclinical, therapeutic and evolutionary profile of vulvar cancer in the population of the eastern region of Morocco. We conducted a retrospective study of all patients treated for vulvar cancer in the Oncology Center, University Hospital Mohammed VI in Oujda, Morocco from June 2007 to January 2014. The study included 34 patients with an average age of 65.7 years, of whom 52.9% were multiparous. The most frequent reason for consultation was pruritus (94.1% of cases). The median of consultation time was 16 months, ranging from 2 months to 8 years. Ignorance and modesty were the major causes of diagnostic delay, since 73.5% of patients already had locally advanced disease at diagnosis. Surgical treatment was proposed to 61.4% of cases and was based on radical vulvectomy associated with bilateral inguinal lymphadenectomy in 68.5% of cases. Adjuvant radiotherapy was indicated in 41.2% of cases, 5.9% of patients underwent neo-adjuvant radiotherapy while 20.6% underwent exclusive radiotherapy associated with concomitant chemotherapy. Palliative chemotherapy was proposed to 8.8% of patients. The overall survival rate at 3 years was 65%, locoregional or distant recurrence rate was 17.3%. Cultural and social characteristics of patients of the eastern region of Morocco treated for vulvar cancer are factors influencing treatment and outcomes. Additional prevention and awareness efforts should be made in order to reduce the rates of locally advanced tumors and to enable curative treatment for this population.
Article
Full-text available
Verrucous carcinoma of the female genital tract is a rare lesion, primarily affecting postmenopausal women. We present a 78-year-old patient with verrucous carcinoma of the vulva, who was admitted to the "Aretaieion" Athens University Hospital. She had complained of vulvar itching during the last two years without visiting a specialist doctor.
Article
For the first time, NCCN Guidelines are available for vulvar cancer, a rare gynecologic cancer. Early-stage cancers can be managed by surgery and observation, and many of these patients can be cured. Lymph node status drives treatment and correlates with survival. Positive groinal nodes require additional therapy, including radiation plus chemotherapy, depending on stage. Sentinel lymph node biopsy is recommended in selected patients.
Article
In the past 28 years, there has been a marked increase in the prevalence of in situ and invasive vulvar carcinoma with the increase of in situ disease occurring primarily in the under 65 age group and peaking at 40 to 49 years. The striking increase in the rates of premalignant lesions in women younger than 50 and other accumulating evidence suggests that the pathogenesis of vulvar cancer may be different in younger and older women. To investigate whether the pathogenesis may be different in these 2 age groups, this retrospective review evaluated prognostic and environmental risk factors associated with squamous cell vulvar cancer in a population of women at age 45 years or younger. The study population was comprised of 56 patients who were diagnosed with the cancer between 1994 and 2006. Their median age was 38 (range: 19-45). Demographic data that were collected and analyzed included a history of smoking, human papillomavirus infection and immunosuppression, and vulvar intraepithelial neoplasia. The median follow-up period was 25.3 months. Stage I disease was identified in 50% (28/56) of the patients. A history of smoking was found in 77% of the cases. In addition to being smokers, women with advanced disease (stage III and IV) had human papillomavirus infection (40%), vulvar intraepithelial neoplasia (46.7%), and were immunocompromised (6.7%). Symptoms longer than 12 months were present in 47% of patients with advanced stage disease. No significant relationship was found between the duration of symptoms and stage (P = 0.42) or positive lymph node metastases (P = 0.28). The disease recurred in 6 patients (10.7%) and three (5.4%) died of their disease. These findings of this small study are consistent with other reports suggesting that risk factors for vulvar cancer are different among younger women compared to the general, older vulvar cancer population. The majority of the risk factors associated with vulvar cancer in younger women appear to be modifiable.
Article
Vulval cancer is rare and should be managed at the cancer centre by appropriately trained specialists working within a multidisciplinary team. Unfortunately, delay in diagnosis is common. Appropriate examination of the vulva is essential. Clinicians should be cautious when lesions or symptoms fail to respond to topical therapy with early recourse to outpatient punch biopsy. Tumours are typically of squamous cell type and spread may occur by lymphatic embolisation at an early stage. Treatment is normally by surgery to achieve both local disease control and assessment of the locoregional lymph nodes. Spread to pelvic lymph nodes is unlikely without involvement of the inguinofemoral lymph nodes, but the incidence increases with the size and number of groin node metastases. Refinement of surgical technique has done much to reduce the physical and psychological impact of this condition, but the morbidity from the inguinofemoral lymphadenectomy remains high. It is hoped that new developments such as sentinel lymph node biopsy may further improve the outcome for women with this cancer. Advanced or recurrent disease poses particular challenges and may well require a multidisciplinary surgical approach in combination with chemoradiation.
Article
Vulvar cancer represents approximately 4% of all gynecologic malignancies and the most important prognosis factor in this cancer is the status of the regional lymph nodes. The radical inguinal lymphadenectomy, associated or not with radiotherapy, is accompanied by high morbidity, which can affect 50% of the patients. The sentinel node detection appears now to be feasible in patients with vulvar carcinoma, in order to reduce the morbidity of inguinal lymphadenectomy. But contrary to breast cancer, the learning curve is not easy to obtain because of the low number of cases. That is why we have described the procedure of selective lymphadenectomy. The aim of this technique is to remove the blue and/or marked inguinal lymph node and any other palpable lymph node, without a real radical inguinal lymphadenectomy. Thus, since November 2003, 4 procedures have been performed in total. With the lymphoscintigraphy, we identified 17 marked lymph node and we finally obtained 28 lymph nodes after surgery, with only one metastatic lymph node. There was no complication after our procedure. Selective lymphadenectomy appears to be a new procedure which may reduce the morbidity of usual inguinal lymphadenectomy.
Article
The breast metastases resulting of vulvar carcinoma are very rare, and represent exceptionally the first manifestation of the disease. We report the case of a 42 year-old patient who underwent a treatment because of vulvar epidermoid carcinoma, right away metastatic at the level of the inguinal ganglia. The treatment consisted in a total vulvectomy with bilateral ganglial curretage, followed by external radiotherapy about the perineum and the inguinal ganglia. Three months after the end of her treatment, the patient presented with a nodula on the left outer breast with features of malignancy noticed by clinic and mammographic examination. The histologic study of the mammary biopsy showed epidermoid carcinoma of likely metastatic origin. A left Patey has been realized and confirmed the metastatic localization of epidermoid carcinoma with axillary ganglial metastasis (2N±7). Besides, this patient presented a right cervical ganglial parcel that the biopsy showed a metastatic localization of a vulvar carcinoma. A palliative chemotherapy type cyclophosphamid, adriblastin, cisplatine (CAP) has been admistrated during three cycles spaced out three weeks. The patient died 11 months after the supervene of the cerebral metastasis. We present this case because its rarety and to show the possibility of metastasis at the level of breast due to vulvar cancer. The clinicians must remember this possible tropism of the vulvar cancer for the breast, not only during the supervision and the complete examination as regards the disease spreading but also when the affection revealed unknown primary tumor. The diagnostic orientation is based on the mammography and the mammary biopsy. In this stage, the treatment is unfortunately palliative, the survival until a year is not more than 20%.
Article
To find out whether the new FIGO staging system (introduced 2009) indeed leads to a more specific prediction of the survival for patients with vulvar SCC. A retrospective study of 269 patients with vulvar SCC from 1988 to 2009. All patients were staged according the old and revised FIGO staging system by histopathological data. Overall survival (OS) and disease specific survival (DSS) were calculated. Of all 269 patients, a total number of 113 patients (42.4%) was restaged according to the new FIGO staging, mainly downstaged. In patients with negative nodes, tumor size was not predictive for OS (p = 0.475) and DSS (p = 0.915). Patients of old FIGO stage III and negative node status showed no difference in survival with the group mentioned above (OS p = 0.105 and DSS p = 0.743, respectively). An increasing number of positive lymph nodes (range 1-9) led to a decrease in survival in OS and DSS (p = 0.022 and p = 0.004 respectively). When corrected for the number of positive nodes, there was no difference in survival between patients with unilateral or bilateral lymph nodes. In patients with positive nodes, extranodal growth showed a significant worse survival compared to patients without extranodal growth (OS p < 0.001 and DSS p = 0.004). The new FIGO staging system provides indeed a better reflection of prognosis for patients with vulvar SCC. An accurate description of clinical and histopathological data combined with information about which FIGO classification has been used is necessary to interpret the literature correctly and to keep the possibility to compare data of different studies.
Article
The objective of the study was to identify prognostic and environmental factors associated with vulvar carcinoma in young women. This study was a review of patients younger than 45 years who were diagnosed with vulvar squamous cell carcinoma between 1994 and 2006. Fifty-six patients were identified. Median age was 38 years and median follow-up was 25.3 months. Fifty-eight percent of patients presented with stage I disease; 77% smoked tobacco. Of patients with advanced disease, 53.3% were smokers, 40% had human papillomavirus (HPV) exposure, 46.7% had a history of vulvar intraepithelial neoplasia (VIN), and 6.7% were immunocompromised. Symptoms were present for more than 12 months in 47%, but symptom duration did not correlate with stage (P = .42) or positive lymph nodes (P = .28). Disease recurred in 10.7% and 5.4% died of disease. Young women with vulvar cancer tend to have early-stage disease, smoke, have a history of HPV, and have VIN. Many of the factors that place these patients at continuous risk are modifiable.